Production (Stage)
Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
-$0.0202-1.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.79% | 46.70% | -120.88% | 52.32% | 32.77% |
| Total Depreciation and Amortization | -18.75% | -19.70% | -9.23% | -4.48% | -4.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 321.76% | -98.91% | 94.87% | -80.36% | 4,150.00% |
| Change in Net Operating Assets | 346.15% | 140.12% | 58.07% | 123.96% | -89.62% |
| Cash from Operations | 46.75% | 68.10% | 48.53% | 75.17% | 23.16% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -93.88% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.02% | -68.44% | -- | -17.53% | -21.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 21.54% | -68.44% | -- | -17.53% | -21.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 377.67% | -91.63% | -588.02% | 282.17% | -141.95% |